Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?

Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab), have ente...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemiale, Virginie, Meert, Anne-Pascale, Vincent, François, Darmon, Michael, Bauer, Philippe R., Van de Louw, Andry, Azoulay, Elie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358632/
https://www.ncbi.nlm.nih.gov/pubmed/30707321
http://dx.doi.org/10.1186/s13613-019-0487-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358632/
https://www.ncbi.nlm.nih.gov/pubmed/30707321
http://dx.doi.org/10.1186/s13613-019-0487-x

Ejemplares similares